Aarti Pharmalabs Limited has formally submitted its Q1 FY27 results presentation to the stock exchanges. The company also stated that the presentation is available on its official website. This release provides investors with key financial and operational highlights for the first quarter of the fiscal year 2027, enabling them to assess the company’s performance and future prospects.
Aarti Pharmalabs Submits Q1 FY27 Results Presentation
Aarti Pharmalabs Limited has officially submitted its Q1 FY27 Results Presentation to the stock exchanges, as per the requirements under Regulation 30 of the SEBI (LODR) Regulations 2015. This presentation offers a comprehensive overview of the company’s performance for the first quarter of the fiscal year 2027.
Key Highlights and Availability
The company has also made this presentation accessible to the public and stakeholders through its corporate website, available at https://www.aartipharmalabs.com/presentation. This accessibility ensures transparency and provides interested parties with detailed insights into the company’s operational and financial status for the period ending June 30, 2026.
Company Snapshot and Capabilities
The presentation highlights Aarti Pharmalabs’ position as a significant player in the pharmaceutical industry, boasting over 25 years of experience. Key strengths include a diverse product portfolio of 220+ products, 500+ global clients, and 3 state-of-the-art R&D facilities. The company operates 7 manufacturing units and 3 USFDA-approved units, with a workforce of over 2,400 employees. It holds a global market share of 15-20% in Xanthine derivatives and maintains a healthy Net Debt/Equity ratio of 0.32x.
Financial Performance Overview (Q1 FY27)
The standalone income statement for Q1 FY27 shows an Operational Revenue of ₹5,346 Mn, with an EBITDA of ₹1,327 Mn and an EBITDA Margin of 24.82%. The standalone Profit After Tax (PAT) stands at ₹713 Mn, with a PAT Margin of 13.34%. The consolidated income statement for the same period reports an Operational Revenue of ₹5,358 Mn, EBITDA of ₹1,326 Mn (24.75% margin), and PAT of ₹761 Mn (14.20% margin).
Growth Strategies and Future Outlook
Aarti Pharmalabs is strategically focused on expanding its capacity and capabilities. The company is undertaking a Brownfield Capex project at Atali Block 2, with an estimated investment of INR 149 crores and an estimated capacity of ~405 KL, focused on CDMO/CMO services. The future outlook targets a 15-18% Revenue & EBITDA CAGR over the next 3-4 years. Additionally, R&D investment in FY27 will focus on TIDES (Peptides & Oligonucleotides) to enhance portfolio capabilities.
Source: BSE
